skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

About Denise

Washington DC, {6D506EDE-F0E4-4964-93FF-D8A3DA23BDA0}

+37 year(s) experience

Denise Peterson Pharma Intelligence
Denise is Editor-In-Chief, Pharma US. Based in Informa’s Washington, DC office, she works with the US Scrip, Pink Sheet and In Vivo editorial team to provide the highest quality strategic insights for pharma's regulatory and commercial readers. 
Denise also collaborates closely with her European and APAC counterparts on editorial initiatives. She has had a colorful history reporting as a senior editor or managing editor on numerous issues for publications now part of Informa's Pink Sheet and Scrip resources. Those include Pink Sheet, Blue Sheet (NIH and public health programs), Beige Sheet (medical technology reimbursement) and Medicare Drug Focus. Her areas of expertise include legislation and health care reimbursement, and she’s also particularly interested in medical ethics. Outside of the office, her interests include culinary history and she is a long-time literacy volunteer.

Analyst Articles

Articles by Kevin

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    J&J's Spravato Set For EU Launches Soon

    23 Oct 2019

    Ketamine-Like Antidepressant Backed By CHMP If the nasal spray is approved by the European Commission, seven months after getting the green light in the US, Spravato will offer the first new mechanism of action in 30 years to treat major depressive disorder.

    Topic drug-approval drug-development-landscape

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Webinar: Q1 2019 Sales and Earnings

    By Kevin Grogan 15 May 2019

    Scrip editors will dissect Q1 sales and earnings reports of top pharma companies and focus on key trends, developments, and projected future impact.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Bayer Bosses Beg Risk-Averse Europe To Rethink

    By Kevin Grogan 07 Mar 2019

    Bayer Bosses Beg Risk-Averse Europe To Rethink

    The German group believes it is going to be at the forefront of development in the cell and gene therapy space but is worried that Europe is failing to recognize the value that the pharma industry and its new technologies can create for society.

    Topic cell-and-gene-therapy